Ownership and insider activity for Viridian Therapeutics, Inc. (VRDN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).
Price
| Price | $24.67 (closing price, October 30, 2026) |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-19 | Tousignant Jennifer | M-Exempt | 10,000 | $144K |
| 2026-08-19 | Tousignant Jennifer | M-Exempt | 10,000 | $144K |
| 2026-08-19 | Tousignant Jennifer | S-Sale | 10,000 | $245K |
| 2026-08-14 | Tripuraneni Radhika | M-Exempt | 40,000 | $528K |
| 2026-08-14 | Tripuraneni Radhika | M-Exempt | 40,000 | $528K |
| 2026-07-01 | CAIN CHRISTOPHER W. | A-Award | 32,341 | $598K |
| 2026-07-01 | Ajer Jeffrey Robert | A-Award | 32,341 | $598K |
| 2026-07-01 | Moses Jennifer K. | A-Award | 32,341 | $598K |
| 2026-07-01 | Gheuens Sarah | A-Award | 32,341 | $598K |
| 2026-07-01 | Kiselak Tomas | A-Award | 32,341 | $598K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.3M | $47.4M | $32.6M | $24.8M | $45.9M | $42.3M | $155.6M | $102.8M | $99.6M | $212.4M |
| Short-term Investments | 0 | 0 | $29.9M | $2.0M | $81.7M | $154.7M | $269.0M | $374.5M | $618.0M | $662.3M |
| Receivables | $524,000 | $1.5M | $24,000 | $108,000 | 0 | $451,000 | $102,000 | $102,000 | 0 | 0 |
| Inventory | $64,000 | 0 | 0 | 0 | 0 | 0 | -$6.6M | 0 | 0 | 0 |
| Total Current Assets | $4.3M | $51.9M | $65.4M | $29.7M | $129.6M | $200.2M | $424.6M | $486.5M | $738.5M | $894.2M |
| Property, Plant & Equipment | $625,000 | $563,000 | $727,000 | $523,000 | $787,000 | $2.1M | $2.9M | $3.3M | $3.4M | $3.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.3M | $52.5M | $66.1M | $30.3M | $131.3M | $203.7M | $435.1M | $490.4M | $742.4M | $899.4M |
| Accounts Payable | $159,000 | $906,000 | $571,000 | $1.1M | $670,000 | $2.3M | $14.2M | $2.2M | $2.1M | $8.7M |
| Short-term Debt | 0 | 0 | $2.3M | $4.0M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.6M | $3.9M | $6.7M | $10.2M | $10.7M | $13.6M | $33.3M | $26.6M | $47.9M | $70.7M |
| Long-term Debt | $2.8M | $9.9M | $8.0M | $4.3M | 0 | 0 | $4.6M | $20.2M | $20.6M | $49.9M |
| Total Liabilities | $4.6M | $14.0M | $14.8M | $14.5M | $11.2M | $16.0M | $40.0M | $48.4M | $70.8M | $177.3M |
| Retained Earnings | -$30.6M | -$93.6M | -$126.3M | -$168.2M | -$278.9M | -$358.3M | -$488.2M | -$725.9M | -$995.9M | -$1.34B |
| Total Equity | -$326,000 | $38.5M | $51.3M | $15.8M | $120.0M | $187.7M | $395.1M | $442.0M | $671.6M | $722.2M |
| Total Debt | $1.0M | $9.9M | $10.3M | $8.3M | $455,000 | $1.0M | $5.3M | $21.0M | $21.1M | $50.7M |
| Net Debt | -$2.3M | -$37.5M | -$52.2M | -$18.5M | -$127.2M | -$195.9M | -$419.3M | -$456.3M | -$696.5M | -$824.0M |
| Working Capital | -$326,000 | $48.0M | $58.6M | $19.6M | $118.9M | $186.5M | $391.2M | $459.8M | $690.6M | $823.5M |
Financial Health
| Debt / Equity | 0.37 |
| Current Ratio | 16.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 6.69 |
Profitability
| Return on Equity | -61.35% |
| Return on Invested Capital | -39.18% |
| Return on Assets | -35.27% |
| Gross Margin | 99.55% |
| Operating Margin | -569.68% |
| Net Margin | -544.06% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of VRDN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks